nach oben

Clinical and Translational Oncology

Erschienen in:

02.11.2017 | Research Article

LOC285629 regulates cell proliferation and motility in colorectal cancer cells

verfasst von: S. N. Nasir, N. Abu, N. S. Ab Mutalib, M. Ishak, I. Sagap, L. Mazlan, I. M. Rose, R. Jamal

Erschienen in: Clinical and Translational Oncology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Colorectal cancer (CRC) is one of the most widely diagnosed cancers in men and women worldwide. With the advancement of next-generation sequencing technologies, many studies have highlighted the involvement of long non-coding RNAs (lncRNAs) in cancer development. Growing evidence demonstrates that lncRNAs play crucial roles in regulating gene and protein expression and are involved in various cancers, including CRC. The field of lncRNAs is still relatively new and a lot of novel lncRNAs have been discovered, but their functional roles are yet to be elucidated. This study aims to characterize the expression and functional roles of a novel lncRNA in CRC.

Method

Several methods were employed to assess the function of LOC285629 such as gene silencing, qPCR, proliferation assay, BrdU assay, transwell migration assay, ELISA and protein profiler.

Results

Via in silico analyses, we identified significant downregulation of LOC285629, a novel lncRNA, across CRC stages. LOC285629 expression was significantly downregulated in advanced stages (Stage III and IV) compared to Stage I (Kruskal–Wallis Test; p = 0.0093). Further in-house validation showed that the expression of LOC285629 was upregulated in colorectal cancer tissues and cell lines compared to the normal counterparts, but was downregulated in advanced stages. By targeting LOC285629, the viability, proliferative abilities, invasiveness and resistance of colorectal cancer cells towards 5-fluorouracil were reduced. It was also discovered that LOC285629 may regulate cancer progression by targeting several different proteins, namely survivin, BCL-xL, progranulin, PDGF-AA, enolase 2 and p70S6 K.

Conclusion

Our findings suggest that LOC285629 may be further developed as a potential therapeutic target for CRC treatment.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. https://doi.org/10.3322/caac.21332.CrossRefPubMed

Abu Hassan MR, Ismail I, Mohd Suan MA, Ahmad F, Wan Khazim WK, Othman Z, et al. Incidence and mortality rates of colorectal cancer in Malaysia. Epidemiol Health. 2016;38:e2016007. https://doi.org/10.4178/epih.e2016007.CrossRefPubMedPubMedCentral

Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47–62. https://doi.org/10.1038/nrg.2015.10.CrossRefPubMed

Wang Y, Zhang D, Wu K, Zhao Q, Nie Y, Fan D. Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. Mol Cell Biol. 2014;34(17):3182–93. https://doi.org/10.1128/mcb.01580-13.CrossRefPubMedPubMedCentral

Iden M, Fye S, Li K, Chowdhury T, Ramchandran R, Rader JS. The lncRNA PVT1 contributes to the cervical cancer Phenotype and associates with poor patient prognosis. PLoS One. 2016;11(5):e0156274. https://doi.org/10.1371/journal.pone.0156274.CrossRefPubMedPubMedCentral

Misawa A, Takayama K-i, Urano T, Inoue S. Androgen-induced long noncoding RNA (lncRNA) SOCS2-AS1 promotes cell growth and inhibits apoptosis in prostate cancer cells. J Biol Chem. 2016;291(34):17861–80. https://doi.org/10.1074/jbc.M116.718536.CrossRefPubMedPubMedCentral

Wu C-H, Hsu C-L, Lu P-C, Lin W-C, Juan H-F, Huang H-C. Identification of lncRNA functions in lung cancer based on associated protein-protein interaction modules. Scientific Rep. 2016;6:35939. https://doi.org/10.1038/srep35939. http://www.nature.com/articles/srep35939#supplementary-information

Yue B, Sun B, Liu C, Zhao S, Zhang D, Yu F, et al. Long non-coding RNA Fer-1-like protein 4 suppresses oncogenesis and exhibits prognostic value by associating with miR-106a-5p in colon cancer. Cancer Sci. 2015;106(10):1323–32. https://doi.org/10.1111/cas.12759.CrossRefPubMedPubMedCentral

Li P, Xue W-J, Feng Y, Mao Q-S. Long non-coding RNA CASC2 suppresses the proliferation of gastric cancer cells by regulating the MAPK signaling pathway. Am J Transl Res. 2016;8(8):3522–9.PubMedPubMedCentral

10.

Saus E, Brunet-Vega A, Iraola-Guzmán S, Pegueroles C, Gabaldón T, Pericay C. Long non-coding RNAs as potential novel prognostic biomarkers in colorectal cancer. Front Genet. 2016;7:54. https://doi.org/10.3389/fgene.2016.00054.CrossRefPubMedPubMedCentral

11.

Wu Z, Wang X, Tang H, Jiang T, Chen J, Lu S, et al. Long non-coding RNA HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer. Oncol Rep. 2014;32(1):395–402.CrossRefPubMed

12.

Zhao W, Song M, Zhang J, Kuerban M, Wang H. Combined identification of long non-coding RNA CCAT1 and HOTAIR in serum as an effective screening for colorectal carcinoma. International Journal of Clinical and Experimental Pathology. 2015;8(11):14131–40.PubMedPubMedCentral

13.

Zheng H-T, Shi D-B, Wang Y-W, Li X-X, Xu Y, Tripathi P, et al. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. Int J Clin Exp Pathol. 2014;7(6):3174–81.PubMedPubMedCentral

14.

Xu C, Yang M, Tian J, Wang X, Li Z. MALAT-1: a long non-coding RNA and its important 3′ end functional motif in colorectal cancer metastasis. Int J Oncol. 2011;39(1):169–75.PubMed

15.

Yang M-H, Hu Z-Y, Xu C, Xie L-Y, Wang X-Y, Chen S-Y, et al. MALAT1 promotes colorectal cancer cell proliferation/migration/invasion via PRKA kinase anchor protein 9. Biochem Biophys Acta. 2015;1852(1):166–74. https://doi.org/10.1016/j.bbadis.2014.11.013.PubMed

16.

Zhao Y, Li H, Fang S, Kang Y, Wu W, Hao Y, et al. NONCODE 2016: an informative and valuable data source of long non-coding RNAs. Nucleic Acids Research. 2016;44(Database issue):203–8. https://doi.org/10.1093/nar/gkv1252.CrossRef

17.

Gebäck T, Schulz MM, Koumoutsakos P, Detmar M. TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. Biotechniques. 2009;46:265–274. https://doi.org/10.2144/000113083 CrossRefPubMed

18.

Jaiswal PK, Goel A, Mittal RD. Survivin: a molecular biomarker in cancer. Indian J Med Res. 2015;141(4):389–97. https://doi.org/10.4103/0971-5916.159250.CrossRefPubMedPubMedCentral

19.

Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14(16):5000.CrossRefPubMed

20.

Choi S, Chen Z, Tang LH, Fang Y, Shin SJ, Panarelli NC et al. Bcl-xL promotes metastasis independent of its anti-apoptotic activity. Nature Commun. 2016;7:10384. doi:10.1038/ncomms10384 http://www.nature.com/articles/ncomms10384#supplementary-information

21.

Jeng PS, Cheng EH. Cancer therapeutics: pulling the plug on BCL-xL. Nat Chem Biol. 2013;9(6):351–2. https://doi.org/10.1038/nchembio.1256.CrossRefPubMed

22.

Scherr A-L, Gdynia G, Salou M, Radhakrishnan P, Duglova K, Heller A, et al. Bcl-xL is an oncogenic driver in colorectal cancer. Cell Death Dis. 2016;7:e2342. https://doi.org/10.1038/cddis.2016.233.CrossRefPubMedPubMedCentral

23.

Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–8.CrossRefPubMed

24.

Pardini B, Kumar R, Naccarati A, Novotny J, Prasad RB, Forsti A, et al. 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes. Br J Clin Pharmacol. 2011;72(1):162–3. https://doi.org/10.1111/j.1365-2125.2010.03892.x.CrossRefPubMedPubMedCentral

25.

Wiebke EA, Grieshop NA, Loehrer PJ, Eckert GJ, Sidner RA. Antitumor effects of 5-fluorouracil on human colon cancer cell lines: antagonism by levamisole. J Surg Res. 2003;111(1):63–9. https://doi.org/10.1016/S0022-4804(03)00053-2.CrossRefPubMed

26.

Han JJ, Yu M, Houston N, Steinberg SM, Kohn EC. Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers. Gynecol Oncol. 2011;120(1):5–10. https://doi.org/10.1016/j.ygyno.2010.09.006.CrossRefPubMed

27.

Yang D, Wang L-L, Dong T-T, Shen Y-H, Guo X-S, Liu C-Y, et al. Progranulin promotes colorectal cancer proliferation and angiogenesis through TNFR2/Akt and ERK signaling pathways. Am J Cancer Res. 2015;5(10):3085–97.PubMedPubMedCentral

28.

Shikada Y, Yonemitsu Y, Koga T, Onimaru M, Nakano T, Okano S, et al. Platelet-Derived growth factor-AA Is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Can Res. 2005;65(16):7241–8. https://doi.org/10.1158/0008-5472.can-04-4171.CrossRef

29.

Heldin C-H. Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal. 2013;11(1):97. https://doi.org/10.1186/1478-811x-11-97.CrossRefPubMedPubMedCentral

30.

Heldin C-H, Östman A, Rönnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta. 1998;1378:79–113.

31.

Vizin T, Kos J. Gamma-enolase: a well-known tumour marker, with a less-known role in cancer. Radiol Oncol. 2015;49(3):217–26. https://doi.org/10.1515/raon-2015-0035.CrossRefPubMedPubMedCentral

32.

Berven LA, Crouch MF. Cellular function of p70S6 K: a role in regulating cell motility. Immunol Cell Biol. 2000;78(4):447–51.CrossRefPubMed

33.

Berven LA, Willard FS, Crouch MF. Role of the p70(S6 K) pathway in regulating the actin cytoskeleton and cell migration. Exp Cell Res. 2004;296:183–95. https://doi.org/10.1016/j.yexcr.2003.12.032.CrossRefPubMed

34.

Xiao L, Wang YC, Li WS, Du Y. The role of mTOR and phospho-p70S6 K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray. J Exp Clin Cancer Res. 2009;28(1):152. https://doi.org/10.1186/1756-9966-28-152.CrossRefPubMedPubMedCentral

Titel: LOC285629 regulates cell proliferation and motility in colorectal cancer cells
verfasst von: S. N. Nasir
N. Abu
N. S. Ab Mutalib
M. Ishak
I. Sagap
L. Mazlan
I. M. Rose
R. Jamal
Publikationsdatum: 02.11.2017
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 6/2018
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-017-1788-x

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

LOC285629 regulates cell proliferation and motility in colorectal cancer cells

Abstract

Purpose

Method

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Method

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain

Transcultural adaptation of the user satisfaction scale to the health service: Brazilian version of the EORTC IN-PATSAT32 questionnaire

Aggressive intrahepatic therapies for synchronous hepatocellular carcinoma with pulmonary metastasis

Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma

No impact of perioperative blood transfusion on prognosis after curative resection for hepatocellular carcinoma: a propensity score matching analysis

Revisiting Dukes’ paradigm; some node positive colon cancer patients have better prognosis than some node negative patients

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie